Global Atosiban Acetate for Injection 麻豆原创 Growth 2024-2030

Publication ID:

LPI10250486

Publication Date:

October 15, 2024

Pages:

113

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Atosiban acetate for injection is a pharmaceutical agent used to manage preterm labor by inhibiting uterine contractions. It is a synthetic peptide that acts as an antagonist at oxytocin receptors, thereby reducing the frequency and intensity of uterine contractions and delaying premature delivery.
The global Atosiban Acetate for Injection market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淎tosiban Acetate for Injection Industry Forecast鈥� looks at past sales and reviews total world Atosiban Acetate for Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Atosiban Acetate for Injection sales for 2024 through 2030. With Atosiban Acetate for Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Atosiban Acetate for Injection industry.
This Insight Report provides a comprehensive analysis of the global Atosiban Acetate for Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Atosiban Acetate for Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Atosiban Acetate for Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Atosiban Acetate for Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Atosiban Acetate for Injection.
United States market for Atosiban Acetate for Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Atosiban Acetate for Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Atosiban Acetate for Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Atosiban Acetate for Injection players cover Ferring Pharmaceuticals, EVER Pharma, Sun Pharma, Zuventus Healthcare, Taj Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Atosiban Acetate for Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
6.75mg per Vial
37.5mg per Vial
75mg per Vial
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Ferring Pharmaceuticals
EVER Pharma
Sun Pharma
Zuventus Healthcare
Taj Pharmaceuticals
Bionika Pharmaceuticals
Nanjing Healthnice Pharmaceutical
Hainan Zhonghe Pharmaceutical
Yangtze River Pharmaceutical Group
Chengdu Tongde Pharmaceutical
Shanxi Weiqida Guangming Pharmaceutical
Chengdu Shengnuo Biotechnology
Hainan General & Kangli Pharmaceutical
Hybio Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Atosiban Acetate for Injection market?
What factors are driving Atosiban Acetate for Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Atosiban Acetate for Injection market opportunities vary by end market size?
How does Atosiban Acetate for Injection break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Atosiban Acetate for Injection Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Atosiban Acetate for Injection by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Atosiban Acetate for Injection by Country/Region, 2019, 2023 & 2030
2.2 Atosiban Acetate for Injection Segment by Type
2.2.1 6.75mg per Vial
2.2.2 37.5mg per Vial
2.2.3 75mg per Vial
2.3 Atosiban Acetate for Injection Sales by Type
2.3.1 Global Atosiban Acetate for Injection Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Atosiban Acetate for Injection Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Atosiban Acetate for Injection Sale Price by Type (2019-2024)
2.4 Atosiban Acetate for Injection Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Atosiban Acetate for Injection Sales by Application
2.5.1 Global Atosiban Acetate for Injection Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Atosiban Acetate for Injection Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Atosiban Acetate for Injection Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Atosiban Acetate for Injection Breakdown Data by Company
3.1.1 Global Atosiban Acetate for Injection Annual Sales by Company (2019-2024)
3.1.2 Global Atosiban Acetate for Injection Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Atosiban Acetate for Injection Annual Revenue by Company (2019-2024)
3.2.1 Global Atosiban Acetate for Injection Revenue by Company (2019-2024)
3.2.2 Global Atosiban Acetate for Injection Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Atosiban Acetate for Injection Sale Price by Company
3.4 Key Manufacturers Atosiban Acetate for Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Atosiban Acetate for Injection Product Location Distribution
3.4.2 Players Atosiban Acetate for Injection Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Atosiban Acetate for Injection by Geographic Region
4.1 World Historic Atosiban Acetate for Injection 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Atosiban Acetate for Injection Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Atosiban Acetate for Injection Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Atosiban Acetate for Injection 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Atosiban Acetate for Injection Annual Sales by Country/Region (2019-2024)
4.2.2 Global Atosiban Acetate for Injection Annual Revenue by Country/Region (2019-2024)
4.3 Americas Atosiban Acetate for Injection Sales Growth
4.4 APAC Atosiban Acetate for Injection Sales Growth
4.5 Europe Atosiban Acetate for Injection Sales Growth
4.6 Middle East & Africa Atosiban Acetate for Injection Sales Growth
5 Americas
5.1 Americas Atosiban Acetate for Injection Sales by Country
5.1.1 Americas Atosiban Acetate for Injection Sales by Country (2019-2024)
5.1.2 Americas Atosiban Acetate for Injection Revenue by Country (2019-2024)
5.2 Americas Atosiban Acetate for Injection Sales by Type (2019-2024)
5.3 Americas Atosiban Acetate for Injection Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Atosiban Acetate for Injection Sales by Region
6.1.1 APAC Atosiban Acetate for Injection Sales by Region (2019-2024)
6.1.2 APAC Atosiban Acetate for Injection Revenue by Region (2019-2024)
6.2 APAC Atosiban Acetate for Injection Sales by Type (2019-2024)
6.3 APAC Atosiban Acetate for Injection Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Atosiban Acetate for Injection by Country
7.1.1 Europe Atosiban Acetate for Injection Sales by Country (2019-2024)
7.1.2 Europe Atosiban Acetate for Injection Revenue by Country (2019-2024)
7.2 Europe Atosiban Acetate for Injection Sales by Type (2019-2024)
7.3 Europe Atosiban Acetate for Injection Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Atosiban Acetate for Injection by Country
8.1.1 Middle East & Africa Atosiban Acetate for Injection Sales by Country (2019-2024)
8.1.2 Middle East & Africa Atosiban Acetate for Injection Revenue by Country (2019-2024)
8.2 Middle East & Africa Atosiban Acetate for Injection Sales by Type (2019-2024)
8.3 Middle East & Africa Atosiban Acetate for Injection Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Atosiban Acetate for Injection
10.3 Manufacturing Process Analysis of Atosiban Acetate for Injection
10.4 Industry Chain Structure of Atosiban Acetate for Injection
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Atosiban Acetate for Injection Distributors
11.3 Atosiban Acetate for Injection Customer
12 World Forecast Review for Atosiban Acetate for Injection by Geographic Region
12.1 Global Atosiban Acetate for Injection 麻豆原创 Size Forecast by Region
12.1.1 Global Atosiban Acetate for Injection Forecast by Region (2025-2030)
12.1.2 Global Atosiban Acetate for Injection Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Atosiban Acetate for Injection Forecast by Type (2025-2030)
12.7 Global Atosiban Acetate for Injection Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Ferring Pharmaceuticals
13.1.1 Ferring Pharmaceuticals Company Information
13.1.2 Ferring Pharmaceuticals Atosiban Acetate for Injection Product Portfolios and Specifications
13.1.3 Ferring Pharmaceuticals Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Ferring Pharmaceuticals Main Business Overview
13.1.5 Ferring Pharmaceuticals Latest Developments
13.2 EVER Pharma
13.2.1 EVER Pharma Company Information
13.2.2 EVER Pharma Atosiban Acetate for Injection Product Portfolios and Specifications
13.2.3 EVER Pharma Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 EVER Pharma Main Business Overview
13.2.5 EVER Pharma Latest Developments
13.3 Sun Pharma
13.3.1 Sun Pharma Company Information
13.3.2 Sun Pharma Atosiban Acetate for Injection Product Portfolios and Specifications
13.3.3 Sun Pharma Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Sun Pharma Main Business Overview
13.3.5 Sun Pharma Latest Developments
13.4 Zuventus Healthcare
13.4.1 Zuventus Healthcare Company Information
13.4.2 Zuventus Healthcare Atosiban Acetate for Injection Product Portfolios and Specifications
13.4.3 Zuventus Healthcare Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Zuventus Healthcare Main Business Overview
13.4.5 Zuventus Healthcare Latest Developments
13.5 Taj Pharmaceuticals
13.5.1 Taj Pharmaceuticals Company Information
13.5.2 Taj Pharmaceuticals Atosiban Acetate for Injection Product Portfolios and Specifications
13.5.3 Taj Pharmaceuticals Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Taj Pharmaceuticals Main Business Overview
13.5.5 Taj Pharmaceuticals Latest Developments
13.6 Bionika Pharmaceuticals
13.6.1 Bionika Pharmaceuticals Company Information
13.6.2 Bionika Pharmaceuticals Atosiban Acetate for Injection Product Portfolios and Specifications
13.6.3 Bionika Pharmaceuticals Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bionika Pharmaceuticals Main Business Overview
13.6.5 Bionika Pharmaceuticals Latest Developments
13.7 Nanjing Healthnice Pharmaceutical
13.7.1 Nanjing Healthnice Pharmaceutical Company Information
13.7.2 Nanjing Healthnice Pharmaceutical Atosiban Acetate for Injection Product Portfolios and Specifications
13.7.3 Nanjing Healthnice Pharmaceutical Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Nanjing Healthnice Pharmaceutical Main Business Overview
13.7.5 Nanjing Healthnice Pharmaceutical Latest Developments
13.8 Hainan Zhonghe Pharmaceutical
13.8.1 Hainan Zhonghe Pharmaceutical Company Information
13.8.2 Hainan Zhonghe Pharmaceutical Atosiban Acetate for Injection Product Portfolios and Specifications
13.8.3 Hainan Zhonghe Pharmaceutical Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Hainan Zhonghe Pharmaceutical Main Business Overview
13.8.5 Hainan Zhonghe Pharmaceutical Latest Developments
13.9 Yangtze River Pharmaceutical Group
13.9.1 Yangtze River Pharmaceutical Group Company Information
13.9.2 Yangtze River Pharmaceutical Group Atosiban Acetate for Injection Product Portfolios and Specifications
13.9.3 Yangtze River Pharmaceutical Group Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Yangtze River Pharmaceutical Group Main Business Overview
13.9.5 Yangtze River Pharmaceutical Group Latest Developments
13.10 Chengdu Tongde Pharmaceutical
13.10.1 Chengdu Tongde Pharmaceutical Company Information
13.10.2 Chengdu Tongde Pharmaceutical Atosiban Acetate for Injection Product Portfolios and Specifications
13.10.3 Chengdu Tongde Pharmaceutical Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Chengdu Tongde Pharmaceutical Main Business Overview
13.10.5 Chengdu Tongde Pharmaceutical Latest Developments
13.11 Shanxi Weiqida Guangming Pharmaceutical
13.11.1 Shanxi Weiqida Guangming Pharmaceutical Company Information
13.11.2 Shanxi Weiqida Guangming Pharmaceutical Atosiban Acetate for Injection Product Portfolios and Specifications
13.11.3 Shanxi Weiqida Guangming Pharmaceutical Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Shanxi Weiqida Guangming Pharmaceutical Main Business Overview
13.11.5 Shanxi Weiqida Guangming Pharmaceutical Latest Developments
13.12 Chengdu Shengnuo Biotechnology
13.12.1 Chengdu Shengnuo Biotechnology Company Information
13.12.2 Chengdu Shengnuo Biotechnology Atosiban Acetate for Injection Product Portfolios and Specifications
13.12.3 Chengdu Shengnuo Biotechnology Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Chengdu Shengnuo Biotechnology Main Business Overview
13.12.5 Chengdu Shengnuo Biotechnology Latest Developments
13.13 Hainan General & Kangli Pharmaceutical
13.13.1 Hainan General & Kangli Pharmaceutical Company Information
13.13.2 Hainan General & Kangli Pharmaceutical Atosiban Acetate for Injection Product Portfolios and Specifications
13.13.3 Hainan General & Kangli Pharmaceutical Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Hainan General & Kangli Pharmaceutical Main Business Overview
13.13.5 Hainan General & Kangli Pharmaceutical Latest Developments
13.14 Hybio Pharmaceutical
13.14.1 Hybio Pharmaceutical Company Information
13.14.2 Hybio Pharmaceutical Atosiban Acetate for Injection Product Portfolios and Specifications
13.14.3 Hybio Pharmaceutical Atosiban Acetate for Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Hybio Pharmaceutical Main Business Overview
13.14.5 Hybio Pharmaceutical Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.